Insider Trading activities of Tricida, Inc. (TCDA)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tricida, Inc. (TCDA) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tricida, Inc. since year 2005. Table 2 shows the detailed insider transactions of Tricida, Inc. since 2005. The reporting company's ticker symbol is TCDA. The reporting company's CIK number is 1595585.
The total value of stock buying since 2005 is $55,788,648.
The total value of stock sales since 2005 is $13,523,688.
The total value of stock option exercises since 2005 is $231,396.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Tricida, Inc. (TCDA).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-07 0 $0 97,808 $3,601,743 66,900 $61,708
2019-04 450,000 $16,200,000 0 $0 0 $0
2019-03 0 $0 269,047 $8,546,792 135,025 $151,888
2019-02 0 $0 14,000 $317,244 4,000 $3,200
2019-01 0 $0 15,349 $319,104 4,000 $3,200
2018-12 0 $0 29,651 $738,805 14,251 $11,400
2018-11 5,000 $148,600 0 $0 0 $0
2018-07 2,075,792 $39,440,048 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Tricida, Inc. insiders (TCDA)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-07-08 Coufal Sandra I Sale 380 34.63 13,159
2019-07-08 Klaerner Gerrit (President and CEO) Sale 2,596 34.63 89,912
2019-07-08 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Sale 3,085 34.67 106,956
2019-07-08 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Option Ex 3,085 .72 2,221
2019-07-05 Coufal Sandra I Sale 1,620 36.22 58,676
2019-07-05 Klaerner Gerrit (President and CEO) Sale 3,230 36.28 117,184
2019-07-05 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Sale 1,615 36.28 58,592
2019-07-05 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Option Ex 1,615 .72 1,162
2019-07-05 Veitinger Klaus R Dr Sale 3,492 36.30 126,749
2019-07-05 Veitinger Klaus R Dr Option Ex 1,100 .80 880
2019-07-03 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 15,407 37.04 570,675
2019-07-03 Otto Dawn Parsell (Sr VP, Clinical Development) Option Ex 15,000 1.39 20,805
2019-07-03 Coufal Sandra I Sale 4,000 37.03 148,120
2019-07-03 Klaerner Gerrit (President and CEO) Sale 6,874 37.08 254,853
2019-07-03 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Sale 3,000 36.91 110,729
2019-07-03 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Option Ex 3,000 .72 2,160
2019-07-03 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 40,401 37.10 1,498,877
2019-07-03 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 40,000 .80 32,000
2019-07-03 Alpern Robert J Sale 3,000 37.05 111,149
2019-07-03 Veitinger Klaus R Dr Sale 9,108 36.90 336,112
2019-07-03 Veitinger Klaus R Dr Option Ex 3,100 .80 2,480
2019-04-03 Orbimed Capital Gp V Llc Buy 225,000 36.00 8,100,000
2019-04-03 Bonita David P Buy 225,000 36.00 8,100,000
2019-03-28 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 15,500 30.74 476,470
2019-03-28 Otto Dawn Parsell (Sr VP, Clinical Development) Option Ex 15,500 .80 12,400
2019-03-28 Coufal Sandra I Sale 2,000 26.70 53,400
2019-03-28 Klaerner Gerrit (President and CEO) Sale 57,822 32.92 1,903,789
2019-03-28 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Sale 6,000 29.99 179,940
2019-03-28 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Option Ex 6,000 .72 4,320
2019-03-28 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 52,925 35.00 1,852,375
2019-03-28 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 52,925 1.64 86,691
2019-03-28 Alpern Robert J Sale 14,000 33.63 470,820
2019-03-28 Veitinger Klaus R Dr Sale 66,300 34.19 2,266,598
2019-03-28 Veitinger Klaus R Dr Option Ex 22,100 .80 17,680
2019-03-26 Veitinger Klaus R Dr Sale 12,000 23.83 285,960
2019-03-26 Veitinger Klaus R Dr Option Ex 4,000 .80 3,200
2019-03-18 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 1,729 25.02 43,259
2019-03-18 Otto Dawn Parsell (Sr VP, Clinical Development) Option Ex 1,729 .80 1,383
2019-03-18 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 14,681 25.23 370,401
2019-03-18 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 14,681 .80 11,744
2019-03-15 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 771 25.02 19,290
2019-03-15 Otto Dawn Parsell (Sr VP, Clinical Development) Option Ex 771 .80 616
2019-03-15 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 1,825 25.02 45,661
2019-03-15 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 1,825 .80 1,460
2019-03-14 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 1,508 25.02 37,730
2019-03-14 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 1,508 .80 1,206
2019-03-13 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 2,000 25.00 50,000
2019-03-13 Otto Dawn Parsell (Sr VP, Clinical Development) Option Ex 2,000 .80 1,600
2019-03-13 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 11,986 25.01 299,769
2019-03-13 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 11,986 .80 9,588
2019-03-04 Klaerner Gerrit (President and CEO) Sale 853 23.76 20,267
2019-03-01 Klaerner Gerrit (President and CEO) Sale 7,147 23.93 171,063
2019-02-28 Coufal Sandra I Sale 2,000 23.04 46,080
2019-02-25 Veitinger Klaus R Dr Sale 12,000 22.60 271,164
2019-02-25 Veitinger Klaus R Dr Option Ex 4,000 .80 3,200
2019-01-30 Coufal Sandra I Sale 28 20.10 562
2019-01-29 Coufal Sandra I Sale 972 20.09 19,527
2019-01-28 Coufal Sandra I Sale 1,000 20.35 20,350
2019-01-28 Veitinger Klaus R Dr Sale 6,000 20.31 121,878
2019-01-28 Veitinger Klaus R Dr Option Ex 2,000 .80 1,600
2019-01-25 Veitinger Klaus R Dr Sale 6,000 20.86 125,178
2019-01-25 Veitinger Klaus R Dr Option Ex 2,000 .80 1,600
2019-01-07 Otto Dawn Parsell (Sr VP, Clinical Development) Sale 665 23.27 15,474
2019-01-02 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 684 23.59 16,135
2018-12-27 Veitinger Klaus R Dr Sale 2,437 23.72 57,798
2018-12-27 Veitinger Klaus R Dr Option Ex 997 .80 797
2018-12-26 Coufal Sandra I Sale 3,400 25.08 85,272
2018-12-26 Klaerner Gerrit (President and CEO) Sale 4,000 25.02 100,080
2018-12-26 Lockey Claire (Chief Dev. Officer and Sr. VP) Sale 10,000 25.06 250,600
2018-12-26 Lockey Claire (Chief Dev. Officer and Sr. VP) Option Ex 10,000 .80 8,000
2018-12-26 Veitinger Klaus R Dr Sale 9,814 24.97 245,055
2018-12-26 Veitinger Klaus R Dr Option Ex 3,254 .80 2,603
2018-11-13 Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) Buy 5,000 29.72 148,600
2018-07-02 Sibling Co-investment Llc (Other) Buy 463,158 19.00 8,800,002
2018-07-02 Coufal Sandra I Buy 463,158 19.00 8,800,002
2018-07-02 Klaerner Gerrit (President and CEO) Buy 15,790 19.00 300,010
2018-07-02 Hejlek Edward J (SVP, General Counsel & Secy.) Buy 13,158 19.00 250,002
2018-07-02 Van Beek Jeroen B (Chief Comm Officer and Sr VP) Buy 5,264 19.00 100,016
2018-07-02 Pietzke Steffen (VP Fin & Chief Acct Officer) Buy 10,527 19.00 200,013
2018-07-02 Hirsch David Buy 131,579 19.00 2,500,001
2018-07-02 Orbimed Capital Gp V Llc Buy 368,421 19.00 6,999,999
2018-07-02 Stahl Wilhelm (Chief Tech Officer & Sr. VP) Buy 13,158 19.00 250,002
2018-07-02 Bonita David P Buy 368,421 19.00 6,999,999
2018-07-02 Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) Buy 60,000 19.00 1,140,000
2018-07-02 Enright Patrick G Buy 131,579 19.00 2,500,001
2018-07-02 Falberg Kathryn E Buy 31,579 19.00 600,001

Insider trading activities including stock purchases, stock sales, and option exercises of TCDA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tricida, Inc. (symbol TCDA, CIK number 1595585) see the Securities and Exchange Commission (SEC) website.